Defining a Cancer Dependency Map

Cited by (1,075)

Items 101–200 of 1,075

1. In silico biological discovery with large perturbation models
   Djordje Miladinovic, Tobias Höppe, Mathieu Chevalley, Andreas Georgiou, Lachlan Stuart, Arash Mehrjou, Marcus Bantscheff, Bernhard Schölkopf, Patrick Schwab · 2025 · Nature Computational Science
2. Synthetic lethality of mRNA quality control complexes in cancer
   Vivian Prindle, Adam E Richardson, Kimberly R Sher, S. Kongpachith, Kaitlin Kentala, Sakina M. Petiwala, Dong Cheng, D. Widomski, Phuong Le, M. Torrent et al. · 2025 · Nature
3. A clinical road map for single-cell omics
   Michael A. Skinnider, Grégoire Courtine, Jocelyne Bloch, Jordan W. Squair · 2025 · Cell
4. Learning and actioning general principles of cancer cell drug sensitivity
   F. Carli, Pierluigi DiChiaro, M. Morelli, C. Arora, L. Bisceglia, Natalia De Oliveira Rosa, A. Cortesi, S. Franceschi, F. Lessi, A. D. Di Stefano et al. · 2025 · Nature Communications
5. mRNA export factors store nascent transcripts within nuclear speckles as an adaptive response to transient global inhibition of transcription.
   Tobias D. Williams, Ewa M. Michalak, Kirstyn T. Carey, E. Lam, Ashley K. Anderson, Esther Griesbach, Yih-Chih Chan, Panagiotis K. Papasaikas, Vicky W. T. Tan, Linh H. Ngo et al. · 2025 · Molecules and Cells
6. CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability
   Yao He, Xiao Tu, Yuxin Xue, Yuxuan Chen, Bengui Ye, Xiaojie Li, Dapeng Li, Zhihui Zhong, Qixing Zhong · 2025 · Journal of Pharmaceutical Analysis
7. Human Organoids as an Emerging Tool for Genome Screenings
   Francesco Andreatta, Delilah F. G. Hendriks, Benedetta Artegiani · 2025 · Annual Review of Biomedical Engineering
8. SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO
   Patrícia Cristine Borck, Isabella Boyle, Kristina Janković, Nolan R. Bick, Kyla J. Foster, Anthony C. Lau, Lucy Parker-Burns, Daniel A. Lubicki, Tianxia Li, Ashir A. Borah et al. · 2025 · Nature
9. Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors
   Zheng-Yan Kan, Ji Wen, V. Bonato, Jennifer Webster, Wen-Jing Yang, Vladimir Ivanov, K. Kim, W. Roh, Chaoting Liu, X. J. Mu et al. · 2025 · Nature Communications
10. TxPert: using multiple knowledge graphs for prediction of transcriptomic perturbation effects.
    Frederik Wenkel, Wilson Tu, Cassandra Masschelein, Hamed Shirzad, Liam Hodgson, Ihab Bendidi, Cian Eastwood, Shawn T. Whitfield, Craig Russell, Yassir El Mesbahi et al. · 2026 · Nature Biotechnology
11. Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer
    Nawaz Khan, U. Raza, Syed Aqib Ali Zaidi, Muhadaisi Nuer, Kayisaier Abudurousuli, Yipaerguli Paerhati, Alifeiye Aikebaier, Wen-Ting Zhou · 2025 · Cancer Biology and Medicine
12. AI-Driven Prediction of Cardio-Oncology Biomarkers Through Protein Corona Analysis
    Mohammad M. Ghassemi, S. Sadeghi, H. H. Kunhiraman, Fei Fang, Qian-Yi Wang, Arshia Rafieioskouei, Shaun Grumelot, H. Gharibi, A. Saei, Maryam Sayadi et al. · 2025 · Chemical Engineering Journal
13. Rapid UPF1 depletion illuminates the temporal dynamics of the NMD-regulated human transcriptome
    Boehm, Volker, Wallmeroth, Damaris, Wulf, Paul O., Popp, Oliver, Teixeira Alves, Luiz Gustavo, Reinecke, Lucie, Riedel, Maximilian, Wyler, Emanuel, Franitza, Marek, Becker, Kerstin et al. · 2025 · Molecular Cell
14. LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?
    Rushil Gupta, Jason S. Hartford, Bang Liu · 2025 · Conference on Empirical Methods in Natural Language Processing
15. Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies
    Andrea Rocca, Lucio Crinò, Luca Braga, F. Salton, B. Ruaro, M. Confalonieri, D. Generali, Paola Confalonieri · 2025 · British Journal of Cancer
16. HRI protein kinase in cytoplasmic heme sensing and mitochondrial stress response: Relevance to hematological and mitochondrial diseases
    Jane-Jane Chen · 2025 · Journal of Biological Chemistry
17. Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma
    Nardone, Christopher, Gao, Jingjing, Seo, Hyuk-Soo, Mintseris, Julian, Ort, Lucy, Yip, Matthew C.J., Negasi, Milen, Besschetnova, Anna K., Kamitaki, Nolan, Gygi, Steven P. et al. · 2025 · Molecular Cell
18. Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs
    Ananthan Sadagopan, Maximilian Carson, Eriks J. Zamurs, Nicholas Garaffo, Heng-Jui Chang, Stuart L. Schreiber, Matthew M. Meyerson, William J. Gibson · 2025 · Nature Chemical Biology
19. Synthetic lethality in cancer drug discovery: challenges and opportunities
    Emanuel Gonçalves, Colm J. Ryan, David J. Adams · 2025 · Nature Reviews Drug Discovery
20. Functional assessment of all ATM SNVs using prime editing and deep learning
    Kwang Seob Lee, Joon-Goo Min, Yumin Cheong, Hyeong-Cheol Oh, Seung-Youn Jung, Jeong‐In Park, Myungjae Song, Jung Hwa Seo, Sung‐Rae Cho, Seokjoong Kim · 2025 · Cell
21. Single-cell RNA sequencing and machine learning provide candidate drugs against drug-tolerant persister cells in colorectal cancer
    Yosui Nojima, Ryoji Yao, Takashi Suzuki · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
22. Target identification and assessment in the era of AI
    Frank W. Pun, Dmitriy I. Podolskiy, Evgeny Izumchenko, Andrew A. Mortlock, Tudor Ionel Oprea, Morten Scheibye‐Knudsen, Kristen Fortney, Eric K. Morgen, Feng Ren, Alex A. Zhavoronkov · 2026 · Nature Reviews Drug Discovery
23. Genetic suppression features ABHD18 as a Barth syndrome therapeutic target
    Sanna N. Masud, Anchal Srivastava, P. Mero, Victoria Saba Echezarreta, Eve Anderson, Lennard van Buren, Jiarun Wei, David Taylor, Adrian Granda Farias, N. Mikolajewicz et al. · 2025 · Nature
24. Uracil-induced replication stress drives mutations, genome instability, anti-cancer treatment efficacy, and resistance.
    O. Mortusewicz, James Haslam, H. Gad, Thomas Helleday · 2025 · Molecules and Cells
25. Are CRISPR Screens Providing the Next Generation of Therapeutic Targets?
    Vazquez, Francisca, Sellers, William R. · 2021 · Cancer Research
26. Targeting FSP1 to induce ferroptosis in chromophobe renal cell carcinoma
    S. Salem, Tie-Gang Han, Michel Alchoueiry, Nadine Mahmoud, Wafaa Bzeih, Joelle Chami, Damir Khabibullin, Hadi Mansour, Yan Tang, Thai H. Ho et al. · 2025 · Oncogene
27. RNA Pol II inhibition activates cell death independently from the loss of transcription
    Nicholas W. Harper, Gavin A Birdsall, Megan E. Honeywell, Kelly M. Ward, Athma A. Pai, Michael J. Lee · 2025 · Cell
28. Compromised epigenetic robustness in cancer: fueling evolution, exposing weakness
    Thomas Stuart Wilson, Paola Scaffidi · 2025 · Trends in cancer
29. MorPhiC Consortium: towards functional characterization of all human genes
    Mazhar Adli, Laralynne Przybyla, Tony Burdett, Paul W. Burridge, Pilar Cacheiro, Howard Y. Chang, J Engreitz, Luke A. Gilbert, William James Greenleaf, Li Hsu et al. · 2025 · Nature
30. YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
    Zhe-Hui Zhu, Rui Ding, Wei Yu, Yun Liu, Zhao-Cai Zhou, Chen-Ying Liu · 2025 · Cell Death and Differentiation
31. Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
    Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas, Daniel Korr, Haruna Tomono, Sawyer Andersen, D.R. Denney, Markus Berger, Volker Schulze et al. · 2025 · Cancer Discovery
32. Tracing the evolution of single-cell 3D genomes in Kras-driven cancers
    Miao Liu, Shengyan Jin, Sherry S. Agabiti, Tyler B Jensen, Tianqi Yang, Jonathan S. D. Radda, Christian F. Ruiz, Gabriel Baldissera, Moein Rajaei, Fangyong Li et al. · 2025 · Nature Genetics
33. Integrating multimodal cancer data using deep latent variable path modelling
    Alex Ing, Álvaro Andrades, Marco Raffaele Cosenza, Jan O. Korbel · 2025 · Nature Machine Intelligence
34. A class of benzofuranoindoline-bearing heptacyclic fungal RiPPs with anticancer activities
    Qiuyue Nie, Fanglong Zhao, Xue-Rong Yu, Mithun C. Madhusudhanan, Caleb Chang, Siting Li, S. Chowdhury, Bryce Kille, Andy Xu, Rory E. Sharkey et al. · 2025 · Nature Chemical Biology
35. Discovery of DCAF16 binders for targeted protein degradation
    Miguel A. Campos, Isabella A. Riha, Chen-Lu Zhang, Chen Mozes, Karl A. Scheidt, Xiao-Yu Zhang · 2025 · ACS Chemical Biology
36. CRISPR screening by AAV episome-sequencing (CrAAVe-seq): a scalable cell-type-specific in vivo platform uncovers neuronal essential genes
    Biswarathan Ramani, Indigo V.L. Rose, Noam Teyssier, Andrew Pan, Spencer Danner-Bocks, Tanya Sanghal, Lin Yadanar, Ruilin Tian, Keran Ma, Jorge J. Palop et al. · 2025 · Nature Neuroscience
37. Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation
    M. Słabicki, Jiho Park, Radosław P. Nowak, Shourya S. Roy Burman, Jesse Pellman, Charles Zou, Hlib Razumkov, Jeannie Carreiro, S. Rastogi, Anna Goldstein et al. · 2025 · Molecules and Cells
38. tRNA modification profiling reveals epitranscriptome regulatory networks in Pseudomonas aeruginosa
    Jingjing Sun, Jun-Zhou Wu, Yi-Feng Yuan, Lei Fan, Wei Lin Patrina Chua, Ya-Nan Ling, S. Balamkundu, Dwijapriya, Hazel Suen Suen Chay, Thomas J. Begley et al. · 2025 · Nucleic Acids Research
39. Zincore, an atypical coregulator, binds zinc finger transcription factors to control gene expression
    Daniëlle Bianchi, Razvan Borza, Erica De Zan, Guizela Huelsz‐Prince, Sebastian Gregoricchio, Marleen Dekker, Alexander Fish, Abdelghani Mazouzi, Lona John Kroese, Simon Linder et al. · 2025 · Science
40. The synthetic lethal interaction between CDS1 and CDS2 is a vulnerability in uveal melanoma and across multiple tumor types
    Pui Ying Chan, Diana Alexander, Ishan Mehta, Larissa Satiko Alcântara Sekimoto Matsuyama, Victoria J. Harle, Rebeca Olvera-León, Jun Sung Park, Fernanda Guadalupe Arriaga-González, Louise van der Weyden, Saamin Cheema et al. · 2025 · Nature Genetics
41. Proteome-wide ligandability maps of drugs with diverse cysteine-reactive chemotypes
    Cai-Ping Tian, Lu Sun, Ke-Ke Liu, Ling Fu, Yi Zhang, Wen-Dong Chen, Fu-Chu He, Jing Yang · 2025 · Nature Communications
42. Subcellular Photocatalysis Enables Tumor-Targeted Inhibition of Thioredoxin Reductase I by Organogold(I) Complexes.
    Mo-Yi Liu, Haitao Liu, Yan Yang, Xiao-Lin Xiong, Tao-Tao Zou · 2025 · Journal of the American Chemical Society
43. Bio-primed machine learning to enhance discovery of relevant biomarkers
    D. Henke, Alexander Renwick, J. Zoeller, Jitendra K Meena, N. Neill, Elizabeth A. Bowling, K. Meerbrey, Thomas F. Westbrook, Lukas M. Simon · 2025 · npj Precision Oncology
44. EcDNA-borne structural variants drive oncogenic fusion transcript amplification
    Hyerim Yi, Shu Zhang, J. Swinderman, Yan-Bo Wang, Vishnupriya Kanakaveti, King L. Hung, I. T. Wong, Suhas Srinivasan, Ellis J Curtis, A. Bhargava-Shah et al. · 2026 · Cell
45. Targeting mitochondrial proteases CLPP and LONP1 via disruption of mitochondrial redox homeostasis induces proteotoxic stress and suppresses tumor progression
    Shivani R. Nandha, Raghavendra S. Patwardhan, Deepak Sharma, Santosh K. Sandur, Rahul Checker · 2025 · Cell Communication and Signaling
46. A STAT3/integrin axis accelerates pancreatic cancer initiation and progression
    Alejandro D. Campos, Ryan M. Shepard, Zachary M. Ortega, Ingrid Heumann, Anna E. Wilke, Arin Nam, Carson Cable, Kourosh Kouhmareh, R. Klemke, Nicole M. Mattson et al. · 2025 · Cell Reports
47. TxPert: Leveraging Biochemical Relationships for Out-of-Distribution Transcriptomic Perturbation Prediction
    Frederik Wenkel, Wilson Tu, Cassandra Masschelein, Hamed Shirzad, Cian Eastwood, Shawn T. Whitfield, Ihab Bendidi, C. Russell, Liam Hodgson, Yassir El Mesbahi et al. · 2025 · arXiv.org
48. UFMylation orchestrates spatiotemporal coordination of RQC at the ER
    Ivan Penchev, Samantha C. Gumbin, Francesco Scavone, Otto Berninghausen, Thomas A. Becker, Ron R. Kopito, Roland Beckmann · 2025 · Science Advances
49. Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation
    Zhi-Jie Deng, Jerrel L. Catlett, Youngeun Lee, Qiong Wu, Zhongli Xu, Ling Xie, Xian Chen, Yan Xiong, H. Kaniskan, Jian Jin · 2025 · Journal of Medicinal Chemistry
50. A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer
    Verónica Rendo, Michaël Schubert, Nicholas Khuu, Maria F. Suárez Peredo Rodríguez, Declan Whyte, Xiao Ling, Anouk van den Brink, Kaimeng Huang, Michelle L. Swift, Yizhou Joseph He et al. · 2025 · Nature Communications
51. Accumulation of succinate suppresses de novo purine synthesis through succinylation-mediated control of the mitochondrial folate cycle
    Mushtaq Ahmad Nengroo, Austin T. Klein, Heather S. Carr, Olivia Vidal-Cruchez, Umakant Sahu, Daniel James McGrail, Nidhi Sahni, Niklas B. Thompson, Peter Allen Faull, Peng Gao et al. · 2025 · Molecular Cell
52. POLR1A inhibits ferroptosis by regulating TFAM-mediated mitophagy and iron homeostasis
    Tuo Zhang, Yan-Yun Gao, Marcell Harhai, Alexis A. Jourdain, T. M. Marti, E. Vassella, Zhang Yang, Qing-Hua Zhou, P. Dorn, Ren-Wang Peng · 2025 · Redox Biology
53. TRIP12 structures reveal HECT E3 formation of K29 linkages and branched ubiquitin chains
    Samuel A. Maiwald, Laura A. Schneider, Ronnald Vollrath, Joanna Liwocha, Matthew D Maletic, Kirby N. Swatek, Monique P. C. Mulder, Brenda Arlene Schulman · 2025 · Nature Structural & Molecular Biology
54. Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer
    Bengisu Dayanc, Sude Eris, Nazife Ege Gulfirat, Gülden Özden-Yılmaz, Ece Çakıroğlu, Ozlem Silan Coskun Deniz, Gökhan Karakülah, Serap Erkek, Şerif Şentürk · 2025 · Cell Death and Disease
55. TACC3 enhances glycolysis in bladder cancer cells through inducing acetylation of c-Myc
    Zhi-Rui Lin, Falian Liang, Gengde Hong, Xizhen Jiang, Qingling Zhang, Mengyao Wang · 2025 · Cell Death and Disease
56. Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer
    A. M. Wong, Hao Huang, A. M. Wong, H. H. Leung, Winnie Cheung, Y. Lam, Xiaofan Ding, Luyao Zhang, Clarice Chu, Yue Liu et al. · 2025 · JHEP Reports
57. DCTPP1: A promising target in cancer therapy and prognosis through nucleotide metabolism.
    Shaoxuan Liu, Li Feng, Zhe Wang · 2025 · Drug Discovery Today
58. Lipid-metabolism-focused CRISPR screens identify enzymes of the mevalonate pathway as essential for prostate cancer growth.
    Gio Fidelito, Izabela Todorovski, L. Cluse, S. Vervoort, Renea A. Taylor, Matthew J. Watt · 2025 · Cell Reports
59. Epstein-Barr virus–driven cardiolipin synthesis sustains metabolic remodeling during B cell transformation
    Haixi You, Larissa Havey, Zhi‐Xuan Li, Yin Wang, John M. Asara, Rui Guo · 2025 · Science Advances
60. Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families
    Li, Lianbo, Meyer, Cynthia, Zhou, Zhi-Wei, Elmezayen, Ammar, Westover, Kenneth · 2022 · Journal of Molecular Biology
61. Advances and Challenges in Drug Screening for Cancer Therapy: A Comprehensive Review
    Shohei Motohashi, Eriko Katsuta, Daisuke Ban · 2025 · Bioengineering
62. Proteome-wide in silico screening for human protein-protein interactions
    Ernst W. Schmid, Helen Zhu, Eunjin Ryu, Yang Lim, Agata Smogorzewska, Alan Brown, Johannes C. Walter · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
63. De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer
    Huan Zhang, Naiara Santana-Codina, Qijia Yu, Clara L. Poupault, Claudia Campos, Xingping Qin, Nicole Sindoni, Marina Ciscar, Aparna Padhye, Miljan Kuljanin et al. · 2025 · Nature Communications
64. MORPH Predicts the Single-Cell Outcome of Genetic Perturbations Across Conditions and Data Modalities
    Chujun He, Jiaqi Zhang, Munther A. Dahleh, Caroline Uhler · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
65. Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma
    John L. Pulice, Matthew M. Meyerson · 2023 · Molecular Cell
66. Mechanisms linking cytoplasmic decay of translation-defective mRNA to transcriptional adaptation
    Mohamed A. El-Brolosy, A. Oak, Ho-Ang An, Yassine Damergi, André Fischer, R. Saunders, Jing-Chuan Luo, Amer Balabaki, J. Guez, Troy W. Whitfield et al. · 2026 · Science
67. Experimental models of pancreas cancer: what has been the impact for precision medicine?
    Vasiliki Pantazopoulou, Casie S. Kubota, Satoshi Ogawa, Kevin Christian Montecillo Gulay, Xiaoxue Lin, Hyemin Song, Jonathan Weitz, Hervé Tiriac, Andrew M. Lowy, Dannielle D. Engle · 2025 · Journal of Clinical Investigation
68. Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors
    William Y. Yang, Qianyu Guo, Songhua Quan, Zachary Rockow Chalmers, J. Brandon Parker, Mihai Ioan Truica, Mary F. Dufficy, Megan M. Kerber, Karthik Vasan, Dikshat Gopal Gupta et al. · 2025 · Science Advances
69. CRAMP1 drives linker histone expression to enable Polycomb repression
    Rachael E. Matthews, Joshua Miguel C. Danac, Emily L Naden, Laura E. Farleigh Smith, Sri Lestari, Akhila Gungi, Alex Appert, Toby Buttress, Ankit Verma, Oliver J. Sinclair et al. · 2025 · Molecular Cell
70. Benchmarking community drug response prediction models: datasets, models, tools, and metrics for cross-dataset generalization analysis
    A. Partin, P. Vasanthakumari, Oleksandr Narykov, Andreas Wilke, Natasha Koussa, Sara E. Jones, Yi-Tan Zhu, Jamie C. Overbeek, Rajeev Jain, G. Fernando et al. · 2025 · Briefings Bioinform.
71. SH3GL1‐activated FTH1 inhibits ferroptosis and confers doxorubicin resistance in diffuse large B‐cell lymphoma
    Ziwen Duan, Wei-Ting Wang, Yan Wang, Rong Wang, W. Hua, Chun-Yu Shang, R. Gao, Hao Shen, Yue Li, Jia-Zhu Wu et al. · 2025 · Clinical and Translational Medicine
72. Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting
    J. R. Lozada, A. Elliott, Mark G. Evans, J. Wacker, Kathleen M. Storey, E. Egusa, Nicholas A. Zorko, Akhilesh Kumar, A. Crymes, Elisabeth I. Heath et al. · 2025 · Cancer Research Communications
73. ENO1–BACE2-mediated LDLR cleavage promotes liver cancer progression by remodelling cholesterol metabolism
    Zhikun Li, Kaixiang Fan, Caixia Suo, Xuemei Gu, Chuxu Zhu, Haoran Wei, Liang Chen, Ping Gao, Linchong Sun · 2025 · Journal of Molecular Cell Biology
74. p53 inactivation drives breast cancer metastasis to the brain through SCD1 upregulation and increased fatty acid metabolism
    Kathrin Laue, S. Pozzi, Johanna Zerbib, Rebecca Bertolio, Yonatan Eliezer, Yael Cohen-Sharir, Tom Winkler, Manuel Caputo, A. Ricci, Lital Adler et al. · 2025 · Nature Genetics
75. Precision oncology in gastric cancer: Shaping the future of personalized treatment
    Cristina Migliore, Elisabetta Fenocchio, Silvia Giordano, Simona Corso · 2025 · Cancer Treatment Reviews
76. Genome-wide CRISPR screen identifies Menin and SUZ12 as regulators of human developmental timing
    Nan Xu, Hyunwoo Cho, James O.S. Hackland, Silvia K. Benito-Kwiecinski, Nathalie G. Saurat, Oliver Harschnitz, Marco Vincenzo Russo, Ralph J. Garippa, Gabriele Ciceri, Lorenz Studer · 2025 · Nature Cell Biology
77. Integrated in vivo functional screens and multiomics analyses identify α-2,3-sialylation as essential for melanoma maintenance
    Praveen Agrawal, Shuhui Chen, A. D. de Pablos, Yellamandayya Vadlamudi, Fatemeh Vand-Rajabpour, Faezeh Jame-Chenarboo, Swarnali Kar, A. Yanke, Pietro Berico, Eleazar Miera Saenz de Vega et al. · 2025 · Science Advances
78. Pioneering new enhancers by GATA3: role of facilitating transcription factors and chromatin remodeling
    Krystal A. Orlando, Sara A. Grimm, Paul A. Wade · 2025 · Nucleic Acids Research
79. Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
    Nitin H. Shirole, Devishi Kesar, Yenarae Lee, Amy B. Goodale, Sudeepa Syamala, Shweta Kukreja, Rong Li, Xintao Qiu, Wenyu Yu, Seth Raphael Goldman et al. · 2025 · Cancer Discovery
80. A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platform
    2025
81. Two decades of PARP inhibitor synthetic lethality in cancer
    Christopher J. Lord, Andrew N.J. Tutt, Alan Ashworth · 2026 · Nature
82. Global genetic interaction network of a human cell maps conserved principles and informs functional interpretation of gene co-essentiality profiles
    Maximilian Billmann, Michael Costanzo, Xiang Zhang, Arshia Zernab Hassan, Mahfuzur Rahman, Kevin R. Brown, Katherine S. Chan, Amy H.Y. Tong, Carles Pons, Henry N. Ward et al. · 2026 · Cell
83. CRISPR/Cas9 Genome Editing in Oncology: Mechanisms, Therapeutic Platforms and Translational Challenges
    Duy Anh Hoang Nguyen, Minh Trong Quang · 2025 · Molecular Biotechnology
84. Uridine-sensitized screening identifies demethoxy-coenzyme Q and NUDT5 as regulators of nucleotide synthesis
    Abigail Strefeler, Zakery N. Baker, Sylvain Chollet, Mads M. Foged, Rachel M. Guerra, J. Ivanisevic, Hector Gallart-Ayala, D. Pagliarini, Alexis A. Jourdain · 2025 · Nature Metabolism
85. RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity
    Shivendra Singh, Jie Fang, Hong-Jian Jin, Lee-Ann Van de Velde, Andrew Cortes, Jiani Chen, Sivaraman Natarajan, E. Poon, Qiong Wu, Christopher L. Morton et al. · 2025 · Nature Communications
86. Identification of breast cancer subtypes and drug response prediction through forward and reverse translation
    J. Karam, P. Rejto, J. Bienkowska, X. J. Mu, W. Roh · 2025 · npj Precision Oncology
87. Pan-cancer, multi-omic correlates of survival transcending tumor lineage across 11,019 patients reveal targets and pathways
    Yiqun Zhang, Fengju Chen, Chad J. Creighton · 2025 · npj Precision Oncology
88. BMAL1 and ARNT enable circadian HIF2α responses in clear cell renal cell carcinoma
    Rebecca M. Mello, Diego Gómez-Ceballos, C. Sandate, Sicong Wang, Céline Jouffe, D. Agudelo, N. Uhlenhaut, N. Thomä, M. Simon, Katja A. Lamia · 2025 · Nature Communications
89. KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavage
    Zheqi Li, Guillermo Peluffo, Laura E. Stevens, Xintao Qiu, Marco Seehawer, Amatullah Tawawalla, Xiao-Yun Huang, Shawn B. Egri, Shaunak Raval, Maeve McFadden et al. · 2025 · Nature Genetics
90. The TEA domain transcription factors TEAD1 and TEAD3 and WNT signaling determine HLA-G expression in human extravillous trophoblasts
    Bowen Gu, Leonardo M R Ferreira, Sebastian Herrera, Lara Brown, Judy Lieberman, Richard I. Sherwood, Torsten B. Meissner, J. Strominger · 2025 · Proceedings of the National Academy of Sciences of the United States of America
91. Metabolic profiling of adult and pediatric gliomas reveals enriched glucose availability in pediatric gliomas and increased fatty acid oxidation in adult gliomas
    Vladislav O. Sviderskiy, Varshini Vasudevaraja, Luiz Gustavo Dubois, James M. Stafford, Elisa K. Liu, Jonathan Serrano, Richard Possemato, Matija Snuderl · 2025 · Acta Neuropathologica Communications
92. Identification of a Selective Anticancer Agent from a Collection of Complex-And-Diverse Compounds Synthesized from Stevioside
    Rachel E Schaaf, Jonathan C K Quirke, M. Ghavami, Emily J Tonogai, Hyang Yeon Lee, Samantha L Barlock, Thomas R Trzupek, K. Abo, M. Rees, Melissa M. Ronan et al. · 2025 · Journal of the American Chemical Society
93. Establishment of a novel mouse model of colorectal cancer by orthotopic transplantation
    Cewen Chen, Qiaochu Fu, Lei Wang, Shinya Tanaka, Masamichi Imajo · 2025 · BMC Cancer
94. KLF5 loss sensitizes cells to ATR inhibition and is synthetic lethal with ARID1A deficiency
    Samah W. Awwad, Colm Doyle, Josie Coulthard, Aldo S. Bader, Nadia Gueorguieva, Simon Lam, Vipul Gupta, R. Belotserkovskaya, Tuan-Anh Tran, Shankar Balasubramanian et al. · 2025 · Nature Communications
95. A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platform
    Jain, Siddhant U., Williamson, Kaylyn E., Ying, Alexander W., Turner, Aasha M., Jiang, Ruidong Jerry, Raval, Shaunak, So, Kevin, Allison, Maxwell J., Sankar, Akshay, Sáme Guerra, Daniel D. et al. · 2026 · Science
96. Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
    Li, Haolong, Melnyk, James E., Fu, Becky Xu Hua, Shrestha, Raunak, Zhang, Meng, Sjöström, Martin, Feng, Siyu, Anderson, Jasmine A., Han, Wanting, Chesner, Lisa N. et al. · 2025 · Nature Genetics
97. Identification of ADAR1i-124: The first effective A-to-I RNA editing inhibitor with promising cancer therapeutic potential
    Moeko Minakuchi, Haoran Zhang, Joel A. Cassel, Yusuke Shiromoto, Jessie Villanueva, Emmanuel Skordalakes, Joseph M. Salvino, Qin Li, Kazuko Nishikura · 2026 · iScience
98. CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen
    N. House, Maxine Chen, Sima Khazaei, Victoria E Brown, Phil Ramsden, David H. Peng, Sydney L Moore, Liang Yuan, Rentian Wu, Fangyang Wang et al. · 2025 · npj Breast Cancer
99. Integrated multi-omics analyses identified the H3K18la-based spatiotemporal characteristics and risk-stratified treatment strategy in lung adenocarcinoma
    Ao Shen, Sufei Zheng, Xiaoya Tang, Yuxin Yao, Enzhi Yin, Nan Sun, Jie He · 2025 · Cancer Letters
100. A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongation.
     J. Devlin, B. Martin, Nenad Bartonicek, Keziah E. Ting, Zheng Fan, Izabela Todorovski, Filip Bjelosevic, Sandra Verschoor, A. Ciccone, Joseph A. Trapani et al. · 2025 · Molecules and Cells